Navigation Links
Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09
Date:11/6/2007

EATONTOWN, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE) announced today that third quarter 2007 revenue increased $2.3 million to $25.7 million from third quarter 2006 revenue of $23.4 million. Revenue from Osteotech's "core" DBM and Hybrid/Synthetic Segments increased 28% to $17.6 million for the three months ended September 30, 2007 as compared to revenue of $13.7 million from the same segments for the third quarter of 2006. Gross margin improved to 55% in the third quarter of 2007 as compared to 49% in the third quarter of 2006. Net income for the three months ended September 30, 2007 was $1.6 million, or $.09 diluted earnings per share, compared to net income of $.2 million, or $.01 diluted earnings per share, for the three months ended September 30, 2006.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "We are very pleased with the results of the productivity initiative started two and one-half years ago to turn the company around. We are very proud of the discipline and focus the team has demonstrated to drive the improvement in gross margin, the increase in our cash position, and the return of the Company to profitability. The team is now focused to deliver new and innovative products and to drive revenue growth."

Revenue for the nine months ended September 30, 2007 increased 5% to $77.3 million from $73.8 million for the nine months ended September 30, 2006. Revenue increased 14% to $49.9 million in the DBM and Hybrid/Synthetic Segments for the nine months ended September 30, 2007 as compared to revenue from the same segments for the nine months ended September 30, 2006 of $43.6 million. Gross margin improved to 51% for the nine months ended Sept
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
2. Osteotech Completes Tissue Supply Agreement With LifeNet Health
3. Osteotech Announces Third Quarter Earnings Release and Conference Call Schedule
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. Haemacure Reports Third Quarter 2007 Results
6. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. MDS Reports Third Quarter 2007 Results
9. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and ... neck pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor ... to earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
(Date:8/28/2015)... ... 28, 2015 , ... Mendon, IL, home of the Adams County Fairgrounds, was ... for a good cause. In its second year, the “Music With A Mission” benefit ... Rehabilitation. The “Mission” of “Music With A Mission” is to raise money to help ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... evaluations for those seeking to go deep sea diving. The act of ... and decompression sickness; for these reasons, it is vital that all recreational and ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive orphan ... general use any time soon, according to educational website Surviving Mesothelioma. Click here ... orphan drug designation for mesothelioma last week from the FDA, will now head into ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2
... VSCP ), a leading provider of quantitative ... exceeds $27 million,compared to $14.7 million at the same ... company calculates backlog as the amount remaining to be,recognized ... studies,included within the backlog ranges from 2 months to ...
... nationally recognized Consumer Watchdog sent a letter today to ... to make health care affordable and available by allowing ... group warned Obama that a proposal pushed by health ... health insurance policies "amounts only to a government-funded customer ...
... Costs as Key , , WASHINGTON, ... Excellence report looks at how states are balancing retiree health care ... , Retiree Health Care in the American States ... care benefits to central human resources (HR) goals; how the states ...
... Diagnostics Incorporated (NYSE: DGX ), the world,s leading ... is scheduled to speak at the Piper Jaffray Healthcare Conference ... Quest Diagnostics presentation is scheduled to begin at 4:00 p.m. ... During the conference, the company will reaffirm its 2008 ...
... Patients treated with radiation prior to surgery for ... and better overall survival rates, according to a recent ... neoadjuvant therapy, which can reduce cancerous tumor size or ... the tumor. Neoadjuvant therapy may include chemotherapy and/or radiation. ...
... probably higher with aprotinin, a drug commonly used to control ... analogues, according to a study http://www.cmaj.ca//cgi/rapidpdf/cmaj.081109 to be ... , On December 3, a Health Canada expert advisory ... is being early released in advance of the meeting. ...
Cached Medicine News:Health News:VirtualScopics Backlog Rises to a Record $27 Million 2Health News:VirtualScopics Backlog Rises to a Record $27 Million 3Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 2Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 3Health News:States View Limits on Retiree Health Benefits 2Health News:Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference 2
(Date:8/27/2015)... Aug. 27, 2015 DURECT Corporation (Nasdaq: ... present at three upcoming healthcare conferences.  ... will present at the Rodman & Renshaw Investment Conference ... The conference is being held at the St. Regis ... A live audio webcast of the presentation will be ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ today ... the commercial development of the company,s supplemental oxygen ... Oxygen device, being developed by ieCrowd,s subsidiary Smart ... patient,s changing demand for oxygen based on level ... (k) submission for the Smart Oxygen device would ...
(Date:8/27/2015)... Lilly and Company (NYSE: LLY ) will attend ... 17, 2015. Sue Mahony , Ph.D., senior vice ... Gaynor , M.D., senior vice president of product development ... a fireside chat at 3:30 p.m., Eastern Daylight Time. ... available on the "Webcasts & Presentations" section of Lilly,s ...
Breaking Medicine Technology:DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... Be Useful in Cancer Treatment,Decisions , SALT LAKE ... (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ) announced today that,it presented ... used to,determine the original location of a metastatic ... meeting of the American Association,for Cancer Research (AACR) ...
... WIRE)--Apr 19, 2007 - King,Pharmaceuticals, Inc. (NYSE:KG) ... results from the Phase III clinical trial,evaluating ... ALTACE(R),(ramipril) diuretic fixed-dose combination product. The Company ... expects to present the,findings in detail at ...
Cached Medicine Technology:Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3King Pharmaceuticals Announces Plan to Report Positive Data from,Phase III Clinical Trial Evaluating the Combination of Altace with,Hydrochlorothiazide 2
... automated, wireless, computerized remote temperature monitoring, ... refrigerator, freezer, incubator and water bath ... and manual temperature log reports., The ... and comes complete with installation, training ...
... water for use, it provides ... physically clean hands when routine ... an option or is not ... return to patient care faster, ...
BioSoft alcohol gel hand antiseptic with soothing moisturizers is a fast-acting, broad-spectrum antimicrobial solution. BioSoft alcohol gel hand antiseptic applies easily, requires no rinsing and dri...
Exidine® 2% CHG Brushless Surgical Scrub offers exceptional persistence and broad-spectrum antimicrobial activity....
Medicine Products: